A215 INJECTION SITE PAIN AND ADHERENCE IN PATIENTS SWITCHING FROM REFERENCE ADALIMUMAB TO AVT02 – INTERIM RESULTS OF THE EASE PAIN TRIAL.
Bibliographic record
Abstract
Abstract Background AVT02, a biosimilar to reference product (RP) adalimumab, was first approved in Canada in 2022. AVT02 is formulated at high concentration and with citrate-free excipients. The EASE PAIN trial is a Phase IV study in Canada evaluating the impact of switching from RP, or an alternative adalimumab biosimilar, to AVT02. Aims The primary objective was to examine the impact of switching on injection site pain across patients in Canada. Secondary objectives included describing the impact of switching on injection site reaction including burning sensation and soreness, treatment adherence, and patient-reported quality of life. Methods The study enrolled patients with gastrointestinal conditions (Crohn’s disease [CD], ulcerative colitis [UC]), rheumatological conditions (rheumatoid arthritis [RA], ankylosing spondylitis [AS], psoriatic arthritis [PsA]), or dermatological conditions (hidradenitis suppurativa [HS], psoriasis [PsO]). Participants were eligible if their treating physician had decided to switch them from low-concentration RP or alternative adalimumab biosimilar to AVT02. The study assesses injection site pain measured via Visual Analog Scale (VAS), adherence, and quality of life (based on EQ-5D-5L) for participants up to Day 180 after switching. The study is currently ongoing (331 Patients enrolled in the Study; 287 included in the interim analysis) Results The intention-to-treat (ITT) population comprised 287 participants. Following the first administration of AVT02, injection site VAS pain score decreased by an average of -18.8 ± 25.51 across the whole population. Supporting this, there was reduction in overall injection site reactions (49.1%), burning sensation (79.4%), and soreness (84.8%) between baseline (RP administration) and follow-up (AVT02 administration). Adherence rate was 95.5% overall. The ITT population maintained high quality of life score (EQ-5D-5L score of >81 on a scale of 1-100) after switching from RP to AVT02. Conclusions The results of this study demonstrate that switching from RP or alternative biosimilar adalimumab to AVT02 leads to decreased injection site pain across all indications, and maintenance of high adherence rates and high quality of life among patients. Funding Agencies None
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.008 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".